OTIC Hits Right Notes, GEMP To Report Data This Month, Busy Year Ahead For RVNC

Gemphire Therapeutics Inc. is all set to announce interim results from COBALT-1, a phase 2b trial designed to investigate Gemcabene in the treatment of homozygous familial hypercholesterolemia, during the week of January 30, 2017.

from RTT - Biotech http://ift.tt/2iOPddi
via IFTTT